Since PSA screening and the treatment that may follow result in trading off one cause of death for another, rather than extending life, providers who support such screening should offer patients a better deal by protecting them from overdiagnosis and overtreatment.

Bookmark

Cite This Study

Welch et al. (Wed,) studied this question.

synapsesocial.com/papers/6a01c66cf58f6e6cfdd8bf8f https://doi.org/https://doi.org/10.1056/nejmms1914228

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1The Threshold Approach to Clinical Decision Making1980 · 1,348 citations
2Reimbursement issues with hormonal therapies for prostate cancer.2005 · 10 citations
3Prostate-Specific Antigen Levels in the United States: Implications of Various Definitions for Abnormal2005 · 154 citations
4Age and Racial Distribution ofProstatic Intraepithelial Neoplasia1996 · 256 citations
5The Role of Increasing Detection in the Rising Incidence of Prostate Cancer1995 · 664 citations

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1The Threshold Approach to Clinical Decision Making1980 · 1,348 citations
2Reimbursement issues with hormonal therapies for prostate cancer.2005 · 10 citations
3Prostate-Specific Antigen Levels in the United States: Implications of Various Definitions for Abnormal2005 · 154 citations
4Age and Racial Distribution ofProstatic Intraepithelial Neoplasia1996 · 256 citations
5The Role of Increasing Detection in the Rising Incidence of Prostate Cancer1995 · 664 citations